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Background: As aromatase-deficient mice, which are deficient in estrogens, reportedly have reduced blood 
pressure, the aromatase gene (CYP19A1) is thought to be a susceptibility gene for essential hypertension (EH). 
The aim of the present study was to investigate the relationship between CYP19A1 and EH by examining single 
nucleotide polymorphisms (SNPs). 
Methods: Five SNPs in the human CYP19A1 gene (rs1870049, rs936306, rs700518, rs10046 and rs4646) were 
selected, and an association study was performed in 218 Japanese EH patients and 225 age-matched 
normotensive (NT) individuals. 
Results: There were significant differences between these groups in the distribution of genotypes rs700518 and 
rs10046 in male subjects, and genotypes rs700518, rs10046 and rs4646 in female subjects. On multiple logistic 
regression analysis, a significant association between rs700518 (p=0.023) and rs10046 (p=0.036) in male subjects 
and rs700518 in female subjects (p=0.018) was noted. Interestingly, the risk genotypes of rs700518 and rs10046 
showed a sex-dependent inverse relationship. Both SBP and DBP levels were higher in total (cases and controls) 
male subjects with the G/G genotype with rs700518 or the T/T genotype with rs10046 than in male subjects 
without the G/G genotype or T/T genotype. SBP levels were lower in female subjects with the G/G genotype 
with rs700518 than in female subjects without G/G. The A-T haplotype constructed with rs1870049 and rs10046 
was a susceptibility marker for EH. 
Conclusions: We confirmed that rs700518 and rs10046, as well as a haplotype constructed with rs1870049 and 
rs10046, in the human CYP19A1 gene can be used as genetic markers for gender-specific EH. 
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Introduction 
High blood pressure or hypertension affects 
about 25% of adults and is an important risk factor for 
death from stroke, myocardial infarction and 
congestive heart failure. The main cause of 
hypertension is a primary condition known as 
essential hypertension (EH). EH is thought to be a 
multifactorial disease [1]. Several reports have 
indicated that there are susceptibility genes for EH, 
including those for estrogen, estrogen receptor [2] and 
aromatase [3]. The final stage of estrogen synthesis is 
catalyzed by aromatase. 
There are numerous proposed mechanisms by 
which estrogen may bring about beneficial effects on 
the cardiovascular system. However, the precise role 
of estrogens has been difficult to establish, perhaps 
due to their wide variety of actions. In humans, 
estrogen facilitates vasodilation by stimulating 
prostacyclin and nitric oxide synthesis, as well as 
decreasing the production of vasoconstrictor 
substances, such as cyclooxgenase-derived products, 
reactive oxygen species, angiotensin II and 
endothelin-1 [4]. Estrogen also reduces the number of 
angiotensin type I (AT1) receptors [5]. Furthermore, 
men are at higher risk of developing cardiovascular 
disease than premenopausal women, and 
age-matched women have been shown to have lower 
blood pressure than men [6]. 
The aromatase enzyme complex catalyzes the Int. J. Med. Sci. 2008, 5 
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conversion of androgens to estrogens in a variety of 
tissues, including the ovary and placenta [7,8], brain 
[9] and adipose tissue [10]. It was recently 
demonstrated that both estrogens and aromatase are 
produced in vascular tissue, particularly in smooth 
muscle cells [11] and endothelial cells [12]. It has been 
reported that aromatase-deficient (ArKO) mice, which 
are deficient in estrogens due to deletion of the 
aromatase gene, exhibit reduced blood pressure 
(BP)[3]. Thus, we hypothesized that aromatase is one 
of the factors affecting BP, and that the aromatase 
gene is a susceptibility gene for hypertension, as single 
nucleotide polymorphisms (SNPs) in this gene are 
associated with differences in estrogen levels in 
human [13]. 
The human CYP19A1 gene, which encodes 
aromatase, consists of 503 amino acids and is located 
on chromosome 15q21.1 [14]. The gene is very unique; 
it contains 11 exons, with 9 exons being translated, 
interrupted by 10 introns (about 80 kb, exon 2a to exon 
2), and consists of approximately 130 kilobase pairs 
(kb). 
The aim of the present study was to investigate 
the relationship between the human CYP19A1 gene 
and EH by examining 5 SNPs in the human CYP19A1 
gene (Figure 1) in Japanese individuals. 
 
Figure 1. Organization of the human CYP19A1 gene and 
location of SNPs. The gene is approximately 130 kilobase pairs 
(kb) in length, and has a total of 11 exons. Boxes indicate exons, 
and lines indicate introns and intergenic regions. Filled boxes 
indicate coding regions. There are two transcript variants; 
variant 1 does not include exon 2a, and thus has a shorter 
5'-UTR than transcript variant 2; variant 2 includes exon 2a. 
Both variants encode the same protein. Polymorphisms were 
expressed as nucleotide number on the sense strand of the 
CYP19A1 gene. 
Subjects and Methods  
Subjects 
EH subjects were 218 patients diagnosed with 
EH according to the following criteria: seated systolic 
blood pressure (SBP) above 160 mmHg and/or 
diastolic blood pressure (DBP) above 100 mmHg, on 3 
occasions within 2 months after the first medical 
examination. None of the EH subjects were using 
anti-hypertensive medication. Patients diagnosed with 
secondary hypertension were excluded. Control 
subjects were 225 healthy, normotensive (NT) 
individuals. None of the controls had a family history 
of hypertension, and they all had SBP and DBP below 
130 and 85 mmHg, respectively. A family history of 
hypertension was defined as prior diagnosis of 
hypertension in grandparents, uncles, aunts, parents 
or siblings. Both groups were recruited from the 
northern area of Tokyo, Japan, and informed consent 
was obtained from each individual according to a 
protocol approved by the Human Studies Committee 
of Nihon University [15]. 
Biochemical analysis 
Plasma concentration of total cholesterol, and 
serum concentrations of creatinine and uric acid were 
measured using the methods of the Clinical 
Laboratory Department of Nihon University Hospital 
[16]. 
Genotyping 
Using information regarding allelic frequencies 
of SNPs registered with the National Center for 
Biotechnology Information (NCBI) and Celera 
Discovery System-Applied Biosystems, 5 SNPs with 
minor allele frequencies greater than 20% were 
selected. SNPs with relatively high minor allele 
frequencies have been shown to be useful as genetic 
markers for genetic association studies. 
We selected 5 SNPs in the human CYP19A1 gene 
as markers for the genetic association experiment (Fig. 
1). All 5 SNPs were confirmed using the NCBI website 
(accession numbers rs1870049, rs936306, rs700518, 
rs10046 and rs4646). rs1870049 and rs936306 are 
located in introns, rs700518 is a synonymous SNP that 
does not result in a change in amino acids, and 
rs10046 and rs4646 are located in the 3’-untranslated 
region. Genotypes were determined using 
Assays-on-Demand kits (Applied Biosystems, 
Branchburg, NJ) together with TaqMan® PCR. When 
allele-specific fluorogenic probes hybridize to the 
template during polymerase chain reaction (PCR), the 
5'-nuclease activity of Taq polymerase is able to 
discriminate between alleles [17]. 
Linkage disequilibrium (LD) analysis and 
haplotype-based case-control analysis 
LD analysis and haplotype-based case-control 
analysis were performed with SNPAlyze version 3.2.3 
(Dynacom Co., Ltd., Yokohama, Japan) using 5 SNPs. 
The software is available from the following website: 
http://www.dynacom.co.jp/products/package/snpa
lyze/index.html. We used |D'| values of >0.5 to 
assign SNP locations to 1 haplotype block. SNPs with 
an r2 v a l u e  o f  < 0 . 5  w e r e  s e l e c t e d  a s  t a g g e d .  I n  t h e  Int. J. Med. Sci. 2008, 5 
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haplotype-based case-control analysis, the frequency 
distribution of the haplotypes was calculated by 
performing a chi-squared test using the contingency 
table method. 
Statistical analysis 
Data are shown as means ±SD. Hardy-Weinberg 
equilibrium was assessed by chi-squared analysis in 
NT controls. The overall distribution of alleles was 
analyzed using 2 × 2 contingency tables, and the 
distribution of genotypes between EH patients and 
NT controls was tested using a 2-sided Fisher exact 
test and multiple logistic regression analysis, as the 
results of multiple logistic regression analyses after 
adjusting for confounding factors are known to be 
highly reliable. Statistical significance was established 
at p < 0.05. Differences in clinical data between the EH 
and NT groups were assessed by student t-test. 
Statistical analyses were performed using SPSS 




Table 1 shows the clinical features of the EH 
patients and NT controls. SBP, DBP, body mass index 
(BMI) and pulse rate were significantly higher in the 
EH group than in the NT group. Age, serum 
concentrations of creatinine, and plasma 
concentrations of total cholesterol and uric acid did 
not significantly differ between the two groups. 
Table 1. Characteristics of study participants. 
 
 
Table 2 shows the distribution of genotypic and 
allelic frequencies of the 5 SNPs in each group. The 
genotype distribution of the each SNP in NT controls 
did not differ significantly from the Hardy-Weinberg 
equilibrium values (data not shown). The overall 
distributions of genotype and allele frequencies of all 5 
SNPs did not significantly differ between the EH and 
total NT groups. However, some distributions showed 
significant gender-based differences between the 
groups. Among men, there were significant 
differences between the EH and NT groups in the 
distribution of rs700518 (P=0.012) and rs10046 
genotypes (P=0.005). In the dominant model, the G/G 
genotype was significantly more frequent than the 
A/A&A/G genotypes of rs700518 (P=0.009), and the 
T/T genotype was significantly more frequent than 
the C/C&C/T genotypes of rs10046 (P=0.003) in EH 
men. Furthermore, the genotype distribution showed 
reciprocal findings in women when compared to men; 
in EH women, the G/G genotype was significantly 
less frequent than the A/A&A/G genotypes of 
rs700518 (P=0.021), and the T/T genotype was 
significantly less frequent than the C/C&C/T 
genotypes of rs10046 (P=0.030). The T allele of SNP 
rs4646 (p=0.046) and the GT&T/T genotype (p=0.032) 
were significantly more frequent in EH women than in 
NT women. 
Multiple logistic regression analysis revealed 
significant associations between rs700518 G/G and 
EH in men (p=0.023) and between rs10046 T/T and 
EH in men (p=0.036), even after adjustment for 
confounding factors such as age, BMI, creatinine, total 
cholesterol and uric acid. The calculated odds ratios 
were 2.48 (95%CI: 1.11-5.53) and 2.10 (95%CI: 
1.04-4.23), respectively. Multiple logistic regression 
analysis revealed a significant association between 
rs700518 A/A&A/G and EH in women (p=0.018), 
even after adjustment for confounding factors such as 
age, BMI, creatinine, total cholesterol and uric acid. 
The calculated odds ratio was 3.31 (95%CI: 1.16-3.40). 
Multiple logistic regression analysis for rs10046 and 
rs4646 in women showed no significant associations 
(data not shown). The opposite direction of the 
association of rs700518 and rs10046 in men and 
women was confirmed by multiple logistic regression 
analysis (p=0.001, <0.001, respectively). Int. J. Med. Sci. 2008, 5 
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Table 2. Genotype and allele distributions among NT subjects and patients with EH. 
 
 
Clinical characteristics of the study participants 
by genotype are shown in Table 3. Genotypes showing 
significant differences in distribution on multiple 
logistic regression analysis were selected for analysis. 
Both SBP and DBP levels were higher in total (EH plus 
NT) male subjects with the G/G genotype in rs700518 
than in male subjects without the G/G genotype. 
Furthermore, both SBP and DBP levels were higher in 
total male subjects with the T/T genotype in rs10046 
than in male subjects without the T/T genotype. In 
contrast, SBP levels were higher in total female 
subjects with the A/A&A/G genotype in 
rs700518than in female subjects without the 
A/A&A/G genotype. 
LD patterns in the CYP19A1 gene are illustrated 
by their |D’| values in NT groups (Table 4). The |D'| 
values indicate that all 5 SNPs are located in 1 
haplotype block, as most |D'| values were over 0.5, 
except for rs1870049-rs700518, rs1870049-rs10046 and 
rs936306-rs10046. All pair-wise SNPs, except 
rs700518-rs10046, were available for the performance 
of a haplotype-based case-control study because all r2 
values were below 0.5. Because r2 values calculated for 
the rs700518 and rs10046 SNPs were large, we did not 
perform a haplotype-based association study using 
the 2 SNPs in the same analysis. All 18 combinations 
of pair-wise SNPs were analyzed in men and women. 
Significant differences in overall distribution were 
only seen for the rs1870049 and rs10046 combination 
in men. Thus, the A-C haplotype is a resistance 
marker for EH, while the A-T haplotype is a 
susceptibility marker for EH. There is no overall 
distribution showing a significant difference in 
women (Table 5). 
 Int. J. Med. Sci. 2008, 5 
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Table 3.  Clinical characteristics of the study partipants in each genotype. 
 
 
Table 4. Pairwise LD in CYP19A1 gene of each NT group. 
 




Human aromatase deficiency was first reported 
in 1995. The disorder is very rare, and only a few cases 
have been reported [18-20]. Male patients with 
aromatase deficiency exhibit eunuchoid skeletal 
proportions, macroorchidism, s e x u a l l y  p r e c o c i t y .  I n  
contrast, female patients with the disease develop 
progressive signs of virilization, pubertal failure with 
no signs of estrogen action, hypergonadotropic 
hypogonadism, polycystic ovaries on pelvic 
sonography, and tall stature. Common clinical data in 
men and women with aromatase deficiency are high 
levels of plasma testosterone, androsterone, FSH and 
LH, and low estradiol and estrone [18,19]. They also 
have homozygous or compound heterozygous 
mutations in the CYP19A1 gene. Interestingly, male 
patients with aromatase deficiency exhibit 
hypertension [19,20]. 
In the present study, the findings regarding 
genotype and allele distributions were particularly 
interesting from the viewpoint of gender differences. 
The gender differences in genotype and allele 
distributions were similar between rs700518 and 
rs10046, while the overall distribution of genotypes 
was significantly different between the EH and the NT 
groups. Blood pressure values for each genotype were Int. J. Med. Sci. 2008, 5 
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similar between rs700518 and rs10046. These results 
were consistent with those of LD analysis showing 
that rs700518 and rs10046 were closely linked with a 
large r2. 
Although systolic BP in ArKO female mice was 
similar to that in age- and weight-matched wild-type 
(WT) mice, diastolic and mean BP were lower in 
ArKO mice (-6.3 ± 1.9 and -4.6 ± 2.1 mmHg, 
respectively). The baroreflex sensitivity of ArKO mice 
w a s  4 6 %  t h a t  o b s e r v e d  i n  W T  m i c e  [ 3 ] .  H o w e v e r ,  
there have been no previous studies on male ArKO 
mice or comparing data between male and female 
ArKO mice. 
Some investigators have been reported the 
CYP19A1 gene variants associated with hypertension. 
Peter et al. found suggestive evidence of 
gender-specific contributions of rs4646 to DBP 
variation in women in the Framingham Heart Study 
[21]. DBP in patients with T/T genotype was 
significantly higher than in those without this 
genotype. This is very interesting because the 
frequencies of EH women with T/T genotype or T 
alleles were significantly higher in the present study 
when compared to NT women. In addition, our data 
for rs4646 also showed no significant results in men, 
which is also in agreement the report by Peter et al. 
Recently, Ramirez-Lorca et al. reported that DBP in 
subjects with C/C genotype in rs10046 was 
significantly higher than in those without C/C 
genotype [22]. This corresponds with our data, as the 
frequency of EH patients with the T/T genotype was 
significantly lower than that of NT subjects. However, 
the opposite direction of the association in men found 
in our study was not detected in men in their study. 
There are several reasons for this discrepancy between 
the results in our study and those of previous studies. 
Our study used a case-control design with patients 
clearly diagnosed by EH criteria, while Ramirez-Lorca 
et al. used a population-based cohort in the general 
population. Therefore, the data on blood pressure in 
each genotype from their study were within normal 
ranges. This discrepancy may be attributed to both the 
different criteria used in subject selection, and to racial 
differences in the populations studied. 
In the present study, none of the SNPs were 
thought to have functional consequences. Possible 
functional mutations in the CYP19A1 gene with 
quantitative effects on genomic transcription, 
posttranslational processing or amino acid sequence 
have a strong linkage with genetic markers such as 
rs10046, and subsequently reduce the activity of 
aromatase associated with EH. Unfortunately, we 
were not able to obtain samples to measure plasma 
sex hormones levels and aromatase activity, due to the 
difficulty in obtaining written informed consent for 
blood examinations from subjects not receiving 
medications. 
In conclusion, the present study was the first to 
examine correlations between the human CYP19A1 
gene (encoding aromatase) and EH. The present data 
indicate that the CYP19A1 gene is a gender-specific 
candidate genetic marker for EH. 
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